Profilin 1 induces drug resistance by downregulating CD138 expression via autophagy in multiple myeloma
Abstract Multiple myeloma (MM), a plasma cell-derived malignant hematological disease, is often treated with bortezomib, a highly effective first-generation proteasome inhibitor. However, resistance to bortezomib is a common occurrence. Profilin 1 (PFN1), a cytoskeleton-related gene known to promote...
Saved in:
| Main Authors: | Ya Wang, ZiYu Dai, Shengying Xiao, Furen Zeng, YiChen Lu |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2025-03-01
|
| Series: | Discover Oncology |
| Online Access: | https://doi.org/10.1007/s12672-025-02036-x |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
THE NEW DIAGNOSTIC FEATURES OF CD138 (SYNDECAN-1) IN MULTIPLE MYELOMA
by: A. F. Karamysheva
Published: (2015-12-01) -
Plasma Cell Myeloma With Lymphoplasmacytic Morphology and Negative CD138 Expression: Case Report and Differential Diagnosis
by: Razan Baloush, et al.
Published: (2022-11-01) -
A Multi-Well Method for the CD138 and AML/MDS FISH Testing of Multiple Biomarkers on a Single Slide in Multiple Myeloma and AML/MDS Patients
by: Frank Tambini, et al.
Published: (2025-06-01) -
Refining precision prognostics in multiple myeloma: loss of miR-221/222 cluster in CD138+ plasma cells results in short-term progression and worse treatment outcome
by: Konstantinos Soureas, et al.
Published: (2025-03-01) -
Construction of a Bacillus subtilis-based expression system for Eimeria acervulina profilin
by: Alfredo Panebra, et al.
Published: (2025-06-01)